UK Prospective Diabetes Study (UKPDS) ( Group.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet1998;352:837-53.
2.
George PB, Tobin KJ, Corpus RA et al. Treatment of cardiac risk factors in diabetic patients: How well do we follow the guidelines?Am Heart J2001;142:857-63.
3.
Storey AM, Perry CJ, Petrie JMEndothelial dysfunction in type 2 diabetes. Brit J Diabetes Vasc Dis2001;1:22-7.
4.
Niles NW, McGrath PD, Malenka D. et al. Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revascularization: results of a large regional prospective study. The New England Cardiovascular Disease Study Group. JACC2001;37: 1008-15.
5.
Van Belle E. , Abolmaali K., Bauters C. et al. Restenosis, late vessel occlusion and left ventricular function six months after balloon angioplasty in diabetic patients. JACC1999; 34:476-85.
6.
Bhatt DL, Chew PD, Robbins MR et al. Elevated baseline CRP levels predict death of MI in diabetic patients undergoing percutaneous coronary intervention. JACC2001;37:66A.
7.
Haffner S W M, Mykkanen L., Festa A. et al. Insulin-resistant pre-diabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing cardiovascular heart disease during the prediabetic state. Circulation2000;101:975-80.
8.
Stern MPDiabetes and cardiovascular disease. The `common soil` hypothesis . Diabetes1995;44:369-74.
9.
Sinha R., Fisch G., Teague B. et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med2002; 346:802-10.
10.
Bao W., Srinivasan SR, Berenson GSPersistent elevation of plasma insulin levels is associated with increased cardiovascular risk in children and young adults. The Bogalusa Heart Study . Circulation1996; 93:54-9.
11.
Berenson GS , Srinivasan SR, Bao W. et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med1998; 338:1650-6.
12.
de Lange M. , Snieder H., Ariens RA et al. The genetics of haemostasis: a twin study. Lancet2001;357:101-05.
13.
Souto JC, Almasy L., Borrell M. et al. Genetic Determinants of Hemostasis Phenotypes in Spanish Families . Circulation2000;101:1546-51.
14.
Freeman MS, Mansfield MW, Barrett JH et al. Genetic contribution to circulating levels of hemostatic factors in healthy families with effects of known genetic polymorphisms on heritability . Arteriosclero Thromb Vasc Biol2002;22:506-10.
15.
Diabetes UK.Diabetes omnibus summary report. Feb - March 2002 available on-line at www.diabetes.org.uk
16.
Matthews DR, Bakst A., Weston WM et al. Rosiglitazone decreases insulin resistance and improves beta cell function in patients with type 2 diabetes. Diabetologia1999; 42 (suppl 1): A228, Abs 858.
17.
Fonseca V., Rosenstock J.Patwardhan R et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes. JAMA2000;283:1695-702.
18.
Bakris G., Dole JF, Porter LE et al. Rosiglitazone improves blood pressure in patients with type 2 diabetes mellitus. Diabetes2000;49 (suppl 1): A96, Abs 388.
19.
GlaxoSmithKline. Data on file (long term).
20.
Brunzell J. , Cohen B., Kreider M. et al. Rosiglitazone favourably affects LDL-C and HDL-C heterogeneity in type 2 diabetes. Diabetes2001; 50: A141, Abs 567.
21.
Freed M., Fuell D., Menci L. et al. Effects of combination therapy with rosiglitazone and glibenclamide on PAI-1 Antigen, PAI-1 Activity, and tPA in patients with type 2 diabetes. Diabetologia2000; 43 (suppl 1);A267 Abs.
22.
Haffner SM, Greenberg AS, Weston WM et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with Type 2 diabetes mellitus. Circulation2002;106:679-84.
